おかえりなさい
アカウント登録
siteでログインする
siteで登録する
受信トレイを確認する
T2C2 Capital
About
T2C2 (Technology, Transfer, Commercialisation, Capital) has the mission to identify in Universities, Research Centres and Industry,
- Montréal,Quebec,Canada
- http://www.t2c2capital.com
Highlights
Details
- Operating Status
- Active
- Investor Type
- Angel Group
T2C2 (Technology, Transfer, Commercialisation, Capital) has the mission to identify in Universities, Research Centres and Industry, business opportunities and turn them into real businesses. Outstanding science, high-quality entrepreneurs, intellectual property and commercial potential are the key elements and criteria that are used to select projects. T2C2 gets involved in the seed phase to support the continuation of the research and to develop the business engineering of the project. Following the seed phase, T2C2 participates with other investors in the financing of the following rounds.
Investments
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Oct 25, 2006
Cytheris
|
Series B | $30.70M | Biopharma | — |
|
Jul 24, 2006
TransPharma Medical
|
Series C | $18M | Biotechnology | — |
|
Oct 10, 2005
Topigen Pharmaceuticals
|
Series B | $6M | Biotechnology | — |
|
May 20, 2005
BioAxone Therapeutic
|
Series B | $12.15M | Biotechnology | — |
|
Jan 18, 2005
Enobia Pharma
|
Series A | $15.55M | Biotechnology | — |
Exits
T2C2 Capital has had 5 exits. T2C2 Capital most notable exits include Cytochroma , TransPharma Medical
| Date | Company Name | Exit Type | Industry | |
|---|---|---|---|---|
| Jan 8, 2013 | Cytochroma | M&A | Biotechnology | Detail |
| Mar 12, 2012 | TransPharma Medical | M&A | Biotechnology | Detail |
| Dec 29, 2011 | Enobia Pharma | M&A | Biotechnology | Detail |
| Nov 4, 2010 | Quazal Technologies | M&A | Gamification | Detail |
| Jan 12, 2010 | Topigen Pharmaceuticals | M&A | Biotechnology | Detail |
